GCP
CYCN icon

GSA Capital Partners’s Cyclerion Therapeutics CYCN Stock Holding History

GSA Capital Partners’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,167
Closed -$71K – 1177
2020
Q4 		$71K Buy
+1,167
New +$79.6K 0.01% 1123

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

GSA Capital Partners's CYCN Position: Q1 2021 in Review

GSA Capital Partners sold out of Cyclerion Therapeutics (CYCN) in Q1 2021, closing a stake of 1,167 shares — an estimated $71K sold.

GSA Capital Partners first reported a position in CYCN in Q4 2020 and held it in 1 quarter. The position peaked at $71K in Q4 2020. 70 funds tracked by Wall St. Rank hold CYCN as of Q1 2021.

  • GSA Capital Partners reported no remaining Cyclerion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • GSA Capital Partners sold 1,167 Cyclerion Therapeutics shares in Q1 2021, an estimated $71K.
  • GSA Capital Partners first reported a position in Cyclerion Therapeutics in Q4 2020 and held it in 1 quarter.
  • GSA Capital Partners's Cyclerion Therapeutics position peaked at $71K in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.